The University of North Carolina at Chapel Hill (UNC), in collaboration with Duke University and the Hamner Institute for Drug Safety Sciences, is well positioned for a T32 training program in clinical pharmacology. We have an outstanding research environment in clinical pharmacology with world-class programs in pharmacogenomics, drug discovery, drug development and drug safety, an outstanding track record of training clinician-scientists in clinical pharmacology, and an excellent applicant pool. The clinical pharmacology training program detailed in this application offers strong leadership, internationally-recognized mentors from multiple disciplines who are actively involved in clinical pharmacology, a wide-array of cutting edge technologies and resources, and a uniquely collaborative environment with strong institutional support. The national applicant pool for this program will be derived primarily from MDs in medical specialty training programs seeking a career path in clinical pharmacology. Trainees, guided by individualized mentoring teams, will complete clinical pharmacology coursework and engage in program-specific activities to gain expertise in all aspects of contemporary clinical pharmacology research, from ethics and pharmacogenomics to clinical trial design. Faculty mentors were chosen based on their productivity in clinical pharmacology research in at least one of four focus areas that form the core of this training program: Drug Disposition and Action;Pharmacogenomics;Drug-induced Organ Toxicity;Quantitative Pharmacology and Clinical Trial Design. A unique feature of this training program is the opportunity to focus on understudied areas in clinical pharmacology, specifically pediatrics and drug safety. The keen interest in clinical pharmacology within our potential trainee pool, the unparalleled investment in clinical pharmacology research resources at UNC, Duke University, and the Hamner-UNC Institute for Drug Safety Sciences, the intellectually-rich regional environment represented by Research Triangle Park with its concentration of biomedical sciences related to clinical pharmacology, and our longstanding excellent research and training infrastructure combine to create a moment of unsurpassed opportunity for training in clinical pharmacology.

Public Health Relevance

There has been an explosion in understanding of the biology underlying disease and interindividual variation in response to pharmacotherapy. This has provided unprecedented opportunities in drug development and the individualization of therapy to treat and ultimately cure disease. The proposed program will produce clinical pharmacologists that will be well-trained to lead the effort to capitalize on these great opportunities.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Special Emphasis Panel (ZGM1)
Program Officer
Okita, Richard T
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Schools of Pharmacy
Chapel Hill
United States
Zip Code
Van Mater, Heather; Balevic, Stephen J; Freed, Gary L et al. (2017) Prescribing for Children with Rheumatologic Disease: Perceived Treatment Approaches between Pediatric and Adult Rheumatologists. Arthritis Care Res (Hoboken) :
Burbank, Allison J; Szefler, Stanley J (2017) Current and future management of the young child with early onset wheezing. Curr Opin Allergy Clin Immunol 17:146-152
Hwang, Michael F; Beechinor, Ryan J; Wade, Kelly C et al. (2017) External Evaluation of Two Fluconazole Infant Population Pharmacokinetic Models. Antimicrob Agents Chemother 61:
Salerno, Sara; Hornik, Christoph P; Cohen-Wolkowiez, Michael et al. (2017) Use of Population Pharmacokinetics and Electronic Health Records to Assess Piperacillin-Tazobactam Safety in Infants. Pediatr Infect Dis J 36:855-859
Cottrell, Mackenzie L; Garrett, Katy L; Prince, Heather M A et al. (2017) Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues. J Antimicrob Chemother 72:1731-1740
Burbank, Allison J; Sood, Amika K; Kesic, Matthew J et al. (2017) Environmental determinants of allergy and asthma in early life. J Allergy Clin Immunol 140:1-12
Parikh, Kishan S; Greiner, Melissa A; Wang, Wei et al. (2017) Representativeness of Medicare Participants in the Jackson Heart Study for African American Medicare Beneficiaries. Epidemiology 28:740-746
Watt, Kevin M; Cohen-Wolkowiez, Michael; Williams, Duane C et al. (2017) Antifungal Extraction by the Extracorporeal Membrane Oxygenation Circuit. J Extra Corpor Technol 49:150-159
Parikh, Kishan S; Greiner, Melissa A; Suzuki, Takeki et al. (2017) Resting Heart Rate and Long-term Outcomes Among the African American Population: Insights From the Jackson Heart Study. JAMA Cardiol 2:172-180
Chan, Austin; Patel, Keyur; Naggie, Susanna (2017) Genotype 3 Infection: The Last Stand of Hepatitis C Virus. Drugs 77:131-144

Showing the most recent 10 out of 119 publications